Brief: Unity Biotechnology Inc Expects Data From Mid-Stage Envision Study In Wet AMD In Q1 2023
09/02/2023 14:07
Feb 9 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY INC - COMPLETE 16- AND 24-WEEK SAFETY
AND
EFFICACY DATA FROM PHASE 2 ENVISION STUDY IN WET AMD EXPECTED IN
Q1 2023
Source text for Eikon: ID:nGNXNj9z6
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force